NCT03452527View on ClinicalTrials.gov

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

April 25, 2019

Study Completion Date

April 25, 2019

Conditions
Choroidal NeovascularizationWet Macular Degeneration
Interventions
BIOLOGICAL

ICON-1

ICON-1 0.6 mg by intravitreal injection

BIOLOGICAL

aflibercept

aflibercept 2 mg by intravitreal injection

Trial Locations (8)

13224

Site 7, Syracuse

19107

Site 6, Philadelphia

78240

Site 5, San Antonio

78503

Site 4, McAllen

78705

Site 1, Austin

90211

Site 2, Beverly Hills

92705

Site 8, Santa Ana

97520

Site 3, Ashland

Sponsors
All Listed Sponsors
lead

Iconic Therapeutics, Inc.

INDUSTRY

NCT03452527 - Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter